VEGFA and neoplasm: That is why the studies were focused on combinations of ipilimumab with other agents such as anti-PD1 blocking antibodies (NCT02311920, NCT04606316, NCT03233152, NCT04817254, NCT04145115, NCT043396860), VEGF inhibitors [156], tumor-treating fields (NCT03430791), TMZ, and radiotherapy (NCT03367715).